Intestinal metabolism and transport of 5-aminosalicylate

被引:0
|
作者
Zhou, SY
Fleisher, D
Pao, LH
Li, C
Winward, B
Zimmermann, EM
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[3] Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to determine the characteristics of intestinal absorption and metabolism of B-aminosalicylic acid (5ASA). Regional perfusions of 5ASA in the anesthetized rat resulted in the appearance of N-acetyl-5-aminosalicylic acid in the intestinal lumen. Lumenal metabolite appearance was proportional to 5ASA permeability, which was 5-fold higher in the jejunum than in the ileum. Intestinal elimination significantly decreases 5ASA absorption at low lumenal drug concentrations and this process is saturated at high drug concentrations. Metabolite levels in intestinal tissue were higher than plasma levels at low perfusion drug concentrations, whereas the reverse was observed at high concentrations. Transport and metabolism of 5ASA was studied in Caco-2 monolayers. At low drug concentrations, 5ASA was preferentially transported in the basolateral (BL) to apical (AP) direction. With 5ASA incubation in either the AP or BL chamber, the N-acetyl metabolite appeared only in the AP compartment. Transport of N-acetyl-5-aminosalicylic acid was also exclusively observed in the BL to AP direction. Clinical data indicate that anti-inflammatory response to oral 5ASA correlates with the amount of BASA delivered to the intestinal tissue. This study shows that at lumenal levels below 200 mu g/ml (concentrations that are typically achieved by controlled release dosage forms), intestinal secretion of 5ASA accounts for more than 50% of the total elimination and can significantly affect tissue levels and, therefore, may be an important factor in determining the response to 5ASA therapy.
引用
收藏
页码:479 / 485
页数:7
相关论文
共 50 条
  • [21] DELIVERY OF 5-AMINOSALICYLATE TO THE GUINEA-PIG CECUM
    SALATA, K
    DULL, BJ
    GOLDMAN, P
    BIOCHEMICAL PHARMACOLOGY, 1987, 36 (02) : 295 - 297
  • [22] Treatment of chronic spontaneous urticaria and angioedema with 5-aminosalicylate
    Barber, C. M.
    Kalicinsky, C.
    ALLERGY, 2017, 72 : 313 - 313
  • [23] Role of 5-Aminosalicylate in Preventing Colorectal Cancer Response
    Bernstein, Charles N.
    Nugent, Zoann
    Blanchard, James F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (09): : 1721 - 1722
  • [24] Regulation of Paracellular Absorption of Cimetidine and 5-Aminosalicylate in Rat Intestine
    Simon Yuji Zhou
    Nusara Piyapolrungroj
    Li-heng Pao
    Cheng Li
    Guangyu Liu
    Ellen Zimmermann
    David Fleisher
    Pharmaceutical Research, 1999, 16 : 1781 - 1785
  • [25] Prospective 2 year study of 5-aminosalicylate nephrotoxicity in the UK
    Muller, AF
    Stevens, PE
    McIntyre, AS
    Ellison, JH
    Logan, RF
    GUT, 2004, 53 : A2 - A2
  • [26] Topical 5-aminosalicylate can be added to high dose (4 g) oral therapy without significant changes to urinary concentrations of 5-aminosalicylate and acetyl-5-aminosalicylate or evidence of renal adverse effects
    Probert, C
    Marteau, P
    Ford, J
    Rademaker, J
    Parkes, M
    Forbes, A
    Riley, S
    Burke, D
    Tham, TCK
    Foldager, M
    GUT, 2005, 54 : A93 - A94
  • [27] Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there?
    Rao, Yuefeng
    Zheng, Feiyue
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (04) : 529 - 531
  • [28] 5-AMINOSALICYLATE AND CHRONIC INFLAMMATORY BOWEL-DISEASE IN CHILDREN
    KLOTZ, U
    KLINISCHE PADIATRIE, 1995, 207 (05): : 285 - 287
  • [29] Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there?
    Yuefeng Rao
    Feiyue Zheng
    International Journal of Clinical Pharmacy, 2013, 35 : 529 - 531